/

Empresas

Im

No verificado

Immune-Onc Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosOncología

2 Comunicados de prensa

Ver todos los comunicados de prensa

27/02/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Industria

Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche

Fuente

Immune-Onc Therapeutics, Inc.

Editor

1.00

0

10/12/2024

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Eventos

Industria

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Fuente

Immune-Onc Therapeutics, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0